Yan Haimeng, He Donghua, Huang Xi, Zhang Enfan, Chen Qingxiao, Xu Ruyi, Liu Xinling, Zi Fuming, Cai Zhen
Bone Marrow Transplantation Centre, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310006, P.R. China.
Department of Haematology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330001, P.R. China.
Oncol Lett. 2018 Jul;16(1):41-47. doi: 10.3892/ol.2018.8649. Epub 2018 May 7.
Interleukin-32 (IL-32), a novel proinflammatory cytokine, is highly expressed in various cancer tissues and in established cancer cell lines. IL-32 has been revealed to serve a crucial role in human cancer development, including tumour initiation, proliferation and maintenance. The expression of IL-32 is regulated by numerous factors, including genetic variations, hypoxia and acidosis in the tumour microenvironment. Understanding the underlying mechanisms of IL-32 expression and its function are critical for the discovery of novel therapeutic strategies that target IL-32. This is a review of the current literature on the regulation and function of IL-32 in cancer progression, focusing on the molecular pathways linking IL-32 and tumour development.
白细胞介素-32（IL-32）是一种新型促炎细胞因子，在各种癌组织和已建立的癌细胞系中高表达。IL-32已被证明在人类癌症发展中起关键作用，包括肿瘤起始、增殖和维持。IL-32的表达受多种因素调节，包括肿瘤微环境中的基因变异、缺氧和酸中毒。了解IL-32表达及其功能的潜在机制对于发现靶向IL-32的新型治疗策略至关重要。本文综述了目前关于IL-32在癌症进展中的调节和功能的文献，重点关注连接IL-32与肿瘤发展的分子途径。
